The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

The days are getting shorter as we "fall back” into standard time and it may be affecting your mood. While we settle into our ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...

Gwee Jo-Ee hopes to raise awareness about suicide prevention by becoming the first woman to swim from Pulau Redang to Pulau ...

In a paper published in Science Bulletin, a Chinese team of scientists made a significant breakthrough in major depressive ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Efforts have been made in recent years to clarify the value of exercise as an adjunctive or independent treatment for major ...

Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

Bipolar disorder can also involve depressive episodes, which have the same symptoms that people with major depressive disorder experience. For most people with bipolar disorder, their first ...

The firm expects to report its 12-month phase 2 data next week, with topline results from a phase 3 trial anticipated in 2026 ...